Pharmaceuticals

Global Non Hodgkin Lymphoma (NHL) Market Overview: Trends Shaping Growth to 2029

November 7, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Expected Total Market Size Of The Non Hodgkin Lymphoma (NHL) Industry By The Forecast Year 2029?

The non hodgkin lymphoma (NHL) market has witnessed substantial expansion in recent years. Its value is expected to rise from $10.11 billion in 2024 to $10.86 billion in 2025, achieving a compound annual growth rate (CAGR) of 7.5%. This historical growth can be attributed to a higher incidence of NHL, significant developments in diagnostics, chemotherapy, and immunotherapy, ongoing clinical research and drug development efforts, and enhanced patient survival rates.

The non-Hodgkin lymphoma (NHL) market size is anticipated to experience robust growth in the coming years. It is projected to expand to $15 billion by 2029, achieving a compound annual growth rate (CAGR) of 8.4%. The projected growth during this period is driven by factors such as an expanding aging population, progress in targeted therapies, innovations in immunotherapy, the adoption of precision medicine approaches, and increasing awareness leading to early detection. Significant trends within the forecast period encompass the rise of biosimilars, the integration of next-generation sequencing, the widespread adoption of CAR-T cell therapies, the introduction of novel chemotherapy agents, and a focus on real-world evidence and outcomes research.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10676&type=smp

Which Drivers Are Supporting Growth Of The Non Hodgkin Lymphoma (NHL) Market?

The non-Hodgkin lymphoma market is anticipated to grow in the future, propelled by the high prevalence of non-Hodgkin lymphoma, a cancer that develops in the lymphatic system, which is a component of the immune system. The prevalence of non-Hodgkin lymphoma indicates the number of people in a population currently diagnosed with or living with the condition at a specific time. Non-Hodgkin lymphoma treatment plays a role in enhancing outcomes for diagnosed individuals by targeting and managing the cancerous cells. For example, in January 2023, the American Cancer Society, a US-based cancer health organization, reported that non-Hodgkin lymphoma makes up 4% of all cancers, and in 2023, it is expected to affect around 80,550 Americans, encompassing 44,880 males and 35,670 females. The organization also estimates that 20,180 people will die in 2023 due to non-Hodgkin lymphoma. Furthermore, in May 2022, according to the Canadian Cancer Society, a Canada-based national cancer charity, 11,400 Canadians would be diagnosed with non-Hodgkin lymphoma in the year 2022, and it would claim the lives of 3,000 Canadians. Consequently, the significant prevalence of non-Hodgkin lymphoma is a key driver for the non-Hodgkin lymphoma market.

Which Key Segments Fueling The Non Hodgkin Lymphoma (NHL) Market?

The non hodgkin lymphoma (nhl) market covered in this report is segmented –

1) By Type: B-Cell Lymphoma, T-Cell Lymphoma

2) By Treatment: Surgery, Stem Cell Transplant, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy

3) By Route of Administration: Oral, Parenteral, Other Routes of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Homecare, Specialty Centers, Other End Users

Subsegments:

1) By B-Cell Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma, Burkitt Lymphoma, Marginal Zone Lymphoma, Primary Mediastinal B-Cell Lymphoma

2) By T-Cell Lymphoma: Peripheral T-Cell Lymphoma (PTCL), Anaplastic Large Cell Lymphoma (ALCL), Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoblastic Lymphoma, Adult T-Cell Leukemia/Lymphoma (ATLL)

What Are The Latest Industry Trends Transforming The Non Hodgkin Lymphoma (NHL) Market?

Drug innovation advancements represent a significant and growing trend within the non-Hodgkin lymphoma market. Companies operating in the non-Hodgkin market are concentrating on developing novel products to maintain their competitive standing. For instance, in December 2022, Genentech Inc., a US-based biotechnology firm, received FDA approval for Lunsumio, a new bispecific antibody intended for treating relapsed or refractory follicular lymphoma. This antibody constitutes a new class of fixed-duration cancer immunotherapy, providing a readily available, off-the-shelf treatment option that negates patient waiting times. The FDA’s clearance is rooted in positive results from the Lunsumio Phase II GO29781 research conducted on individuals with extensively pretreated FL, particularly those at a high risk of illness progression or unresponsive to prior treatments.

Which Leading Companies Dominate The Non Hodgkin Lymphoma (NHL) Market Share?

Major companies operating in the non hodgkin lymphoma (NHL) market include Bayer AG, Teva Pharmaceutical Industries Ltd., F. Hoffmann La Roche Ltd., Merck & Co. Inc., Eli Lilly and Co., Novartis AG, GlaxoSmithKline plc, AbbVie Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Bristol Myers Squibb Co., Pfizer Inc., Celgene Corporation, Sanofi S.A., Janssen Pharmaceuticals Inc., Johnson & Johnson, Biogen Idec, Boehringer Ingelheim GmbH, Eisai Co. Ltd., Gilead Sciences, Incyte Corporation, Karyopharm Therapeutics, Kite Pharma Inc., Kyowa Hakko Kirin Co. Ltd., MorphoSys AG, Nordic Nanovector ASA, Ono Pharmaceutical Co. Ltd., Seattle Genetics Inc., Spectrum Pharmaceuticals Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

Which Region Currently Holds The Largest Share Of The Non Hodgkin Lymphoma (NHL) Market?

North America was the largest region in the non-Hodgkin lymphoma (NHL) market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global non-Hodgkin lymphoma (NHL) market report during the forecast period. The regions covered in the non-Hodgkin lymphoma (NHL) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Non Hodgkin Lymphoma (NHL) Market Report:

https://www.thebusinessresearchcompany.com/customise?id=10676&type=smp

Browse Through More Reports Similar to the Global Non Hodgkin Lymphoma (NHL) Market 2025, By The Business Research Company

Data Protection As A Service Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/data-protection-as-a-service-global-market-report

Cloud Security Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cloud-security-global-market-report

Application Security Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/application-security-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795